JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

AZN

73.59

-1.31%↓

NVS

116.79

+0.8%↑

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

AbbVie Inc

Затворен

СекторЗдравеопазване

198.07 -0.35

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

198

Максимум

198.64

Ключови измерители

By Trading Economics

Приходи

1.3B

1.3B

Продажби

2.1B

15B

P/E

Средно за сектора

92.578

34.393

EPS

2.97

Дивидентна доходност

3.31

Марж на печалбата

9.66

Служители

55,000

EBITDA

-4.3B

117M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+9.3% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

3.31%

2.54%

Следващи печалби

29.10.2025 г.

Следваща дата на дивидент

15.08.2025 г.

Следваща дата на екс-дивидент

14.10.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

12B

348B

Предишно отваряне

198.42

Предишно затваряне

198.07

Настроения в новините

By Acuity

22%

78%

40 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

AbbVie Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.07.2025 г., 12:46 ч. UTC

Печалби

AbbVie 2Q Results Top Wall Street's Forecasts with Boost from Skyrizi, Rinvoq Sales

30.06.2025 г., 13:02 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1 Billion in Cash

25.04.2025 г., 13:57 ч. UTC

Печалби

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised -- Update

25.04.2025 г., 12:52 ч. UTC

Печалби

AbbVie 1Q Revenue Up on Soaring Skyrizi, Rinvoq Sales; Outlook Raised

31.07.2025 г., 12:08 ч. UTC

Печалби

AbbVie Stock Pops After Earnings Beat and Guidance Raised -- Barrons.com

31.07.2025 г., 11:46 ч. UTC

Печалби

AbbVie Raises FY Outlook

31.07.2025 г., 11:44 ч. UTC

Печалби

AbbVie 2Q Global Net Rev From Oncology Portfolio $1.68B >ABBV

31.07.2025 г., 11:44 ч. UTC

Печалби

AbbVie 2Q Global IMBRUVICA Rev $754M >ABBV

31.07.2025 г., 11:44 ч. UTC

Печалби

AbbVie 2Q Global Skyrizi Rev $4.42B >ABBV

31.07.2025 г., 11:44 ч. UTC

Печалби

AbbVie 2Q Adj EPS $2.97 >ABBV

31.07.2025 г., 11:44 ч. UTC

Печалби

AbbVie 2Q U.S. HUMIRA Rev $802M >ABBV

31.07.2025 г., 11:44 ч. UTC

Печалби

AbbVie Sees FY Adj EPS $11.88-Adj EPS $12.08 >ABBV

31.07.2025 г., 11:44 ч. UTC

Печалби

AbbVie 2Q EPS 52c >ABBV

31.07.2025 г., 11:44 ч. UTC

Печалби

AbbVie 2Q Rev $15.42B >ABBV

31.07.2025 г., 11:44 ч. UTC

Печалби

AbbVie 2Q International HUMIRA Rev $378M >ABBV

31.07.2025 г., 11:44 ч. UTC

Печалби

AbbVie 2Q Net $938M >ABBV

30.06.2025 г., 12:47 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Agrees to Acquire Capstan Therapeutics for $2.1B in Cash

30.06.2025 г., 12:33 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Will Acquire Capstan, Including CPTX2309, a Potential First-In-Class in Vivo tLNP anti-CD19 CAR-T Therapy Candidate >ABBV

30.06.2025 г., 12:33 ч. UTC

Придобивния, сливания и поглъщания

AbbVie : Proposed Acquisition Strengthens Commitment to Transforming Patient Care With Capstan's Innovative tLNP Platform Technology >ABBV

30.06.2025 г., 12:32 ч. UTC

Придобивния, сливания и поглъщания

AbbVie Will Pay Up to $2.1B in Cash at Closing to Acquire Capstan >ABBV

30.06.2025 г., 12:31 ч. UTC

Придобивния, сливания и поглъщания

AbbVie To Acquire Capstan Therapeutics, Further Strengthening Commitment To Transforming Patient Care In Immunology >ABBV

7.05.2025 г., 09:30 ч. UTC

Топ новини

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

28.04.2025 г., 12:44 ч. UTC

Печалби

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

28.04.2025 г., 09:33 ч. UTC

Печалби

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25.04.2025 г., 16:03 ч. UTC

Печалби

AbbVie Stock Rises Despite Risks as Earnings Beat Forecasts -- Barrons.com

25.04.2025 г., 14:00 ч. UTC

Топ новини
Печалби

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25.04.2025 г., 12:24 ч. UTC

Топ новини
Печалби

AbbVie Stock Jumps as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25.04.2025 г., 12:03 ч. UTC

Топ новини
Печалби

AbbVie Stock Rises as Earnings Beat, Guidance Raised. But Tariffs Could Bite Yet. -- Barrons.com

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q U.S. HUMIRA Rev $744M >ABBV

25.04.2025 г., 11:43 ч. UTC

Печалби

AbbVie 1Q International HUMIRA Rev $377M >ABBV

Сравнение с други в отрасъла

Ценова промяна

AbbVie Inc Прогноза

Ценова цел

By TipRanks

9.3% нагоре

12-месечна прогноза

Среден 216.47 USD  9.3%

Висок 255 USD

Нисък 170 USD

Според 17 анализатори от Wall Street, предложили 12-месечна ценова цел за AbbVie Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

17 ratings

11

Купи

6

Задържане

0

Продай

Техническа оценка

By Trading Central

180.37 / 195.54Подкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Bearish Evidence

Дългосрочен план

Bearish Evidence

Настроение

By Acuity

40 / 374 Класиране в Здравеопазване

Настроения в новините

Много силни бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.